Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Fundamental Analysis

NASDAQ:IOBT - Nasdaq - US4497781090 - Common Stock - Currency: USD

0.9  -0.01 (-1.56%)

After market: 0.8999 0 (-0.01%)

Fundamental Rating

2

Overall IOBT gets a fundamental rating of 2 out of 10. We evaluated IOBT against 571 industry peers in the Biotechnology industry. The financial health of IOBT is average, but there are quite some concerns on its profitability. IOBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IOBT has reported negative net income.
IOBT had a negative operating cash flow in the past year.
In the past 5 years IOBT always reported negative net income.
In the past 5 years IOBT always reported negative operating cash flow.
IOBT Yearly Net Income VS EBIT VS OCF VS FCFIOBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -100.44%, IOBT is doing worse than 74.78% of the companies in the same industry.
IOBT has a Return On Equity (-124.50%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -100.44%
ROE -124.5%
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IOBT Yearly ROA, ROE, ROICIOBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IOBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOBT Yearly Profit, Operating, Gross MarginsIOBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, IOBT has more shares outstanding
IOBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IOBT Yearly Shares OutstandingIOBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
IOBT Yearly Total Debt VS Total AssetsIOBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

IOBT has an Altman-Z score of -5.66. This is a bad value and indicates that IOBT is not financially healthy and even has some risk of bankruptcy.
IOBT has a Altman-Z score of -5.66. This is in the lower half of the industry: IOBT underperforms 63.40% of its industry peers.
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.66
ROIC/WACCN/A
WACCN/A
IOBT Yearly LT Debt VS Equity VS FCFIOBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 5.37 indicates that IOBT has no problem at all paying its short term obligations.
IOBT has a Current ratio (5.37) which is comparable to the rest of the industry.
IOBT has a Quick Ratio of 5.37. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
IOBT has a Quick ratio (5.37) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 5.37
IOBT Yearly Current Assets VS Current LiabilitesIOBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.31% over the past year.
EPS 1Y (TTM)44.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IOBT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.87%
EPS Next 2Y17.05%
EPS Next 3Y13.02%
EPS Next 5Y13.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IOBT Yearly Revenue VS EstimatesIOBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
IOBT Yearly EPS VS EstimatesIOBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IOBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IOBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOBT Price Earnings VS Forward Price EarningsIOBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOBT Per share dataIOBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOBT's earnings are expected to grow with 13.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.05%
EPS Next 3Y13.02%

More info and screens

0

5. Dividend

5.1 Amount

IOBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IO BIOTECH INC

NASDAQ:IOBT (3/5/2025, 8:04:23 PM)

After market: 0.8999 0 (-0.01%)

0.9

-0.01 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners67.38%
Inst Owner Change-16.52%
Ins Owners0.34%
Ins Owner Change0.27%
Market Cap59.29M
Analysts78.33
Price Target9.18 (920%)
Short Float %0.04%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.8%
Min EPS beat(2)-22.76%
Max EPS beat(2)13.17%
EPS beat(4)2
Avg EPS beat(4)1.91%
Min EPS beat(4)-22.76%
Max EPS beat(4)18.3%
EPS beat(8)4
Avg EPS beat(8)0.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.76%
EPS NQ rev (1m)-1.3%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS1.1
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.44%
ROE -124.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 5.37
Altman-Z -5.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.28%
EPS Next Y35.87%
EPS Next 2Y17.05%
EPS Next 3Y13.02%
EPS Next 5Y13.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y-12.25%
EBIT Next 5YN/A
FCF growth 1Y-27.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.72%
OCF growth 3YN/A
OCF growth 5YN/A